Author

Muhammad Al‐Hajj

Observed names: M Al-Hajj, M. Al-Hajj, Muhammad A. Al-Hajj, Muhammad Al-Hajj, Muhammad Ali Al-Hajj, Muhammad A. Al-Hajj

Observed institutions: Genomics Institute of the Novartis Research Foundation, Howard Hughes Medical Institute, GlaxoSmithKline (United Kingdom), University of Michigan, GlaxoSmithKline (United States), Michigan Medicine, Autolus (United Kingdom), U-M Rogel Cancer Center

ORCID: 0000-0001-5423-0758

Observed ORCID: 0000-0001-5423-0758

OpenAlex ID: A5079191784

Prospective identification of tumorigenic breast cancer cells

2003 · Muhammad Al-Hajj, Max S. Wicha, et al. · Proceedings of the National Academy of Sciences · 10,621

Self-renewal and solid tumor stem cells

2004 · Muhammad Al-Hajj, Michael F Clarke · Oncogene · 923

Stem cells in normal breast development and breast cancer

2003 · Gabriela Dontu, Muhammad Al‐Hajj, et al. · Cell Proliferation · 602

PDF

Therapeutic implications of cancer stem cells

2003 · Muhammad Al-Hajj, Michael W Becker, et al. · Current Opinion in Genetics & Development · 573

Stem cells in normal breast development and breast cancer

2003 · MS Wicha, G Dontu, et al. · Breast Cancer Research · 536

PDF

CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial

2021 · Shaun Cordoba, Shimobi Onuoha, et al. · Nature Medicine · 302

PDF

Antitumor activity without on-target off-tumor toxicity of GD2–chimeric antigen receptor T cells in patients with neuroblastoma

2020 · Karin Straathof, Barry Flutter, et al. · Science Translational Medicine · 205

PDF

In Vivo RNAi Screening Identifies a Leukemia-Specific Dependence on Integrin Beta 3 Signaling

2013 · Peter G. Miller, Fatima Al-Shahrour, et al. · Cancer Cell · 163

PDF

Cancer stem cells and oncology therapeutics

2006 · Muhammad Al-Hajj · Current Opinion in Oncology · 149

ABCB8 Mediates Doxorubicin Resistance in Melanoma Cells by Protecting the Mitochondrial Genome

2009 · Aaron M. Elliott, Muhammad A. Al-Hajj · Molecular Cancer Research · 127

Phase 1 First-in-Human Study of AUTO2, the First Chimeric Antigen Receptor (CAR) T Cell Targeting APRIL for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

2019 · Rakesh Popat, Sonja Zweegman, et al. · Blood · 50

Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy

2023 · Lydia Lee, Wen Chean Lim, et al. · Journal for ImmunoTherapy of Cancer · 49

PDF

Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR T cell therapy, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL.

2020 · Wendy Osborne, Maria Marzolini, et al. · Journal of Clinical Oncology · 43

Phase I Study of AUTO3, a Bicistronic Chimeric Antigen Receptor (CAR) T-Cell Therapy Targeting CD19 and CD22, in Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL): Amelia Study

2019 · Persis J Amrolia, Robert Wynn, et al. · Blood · 41

Simultaneous Targeting of CD19 and CD22: Phase I Study of AUTO3, a Bicistronic Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL): Amelia Study

2018 · Persis J Amrolia, Robert Wynn, et al. · Blood · 34

The ABCs of cancer stem cell drug resistance.

2010 · Aaron Elliott, Aaron Elliot, et al. · PubMed · 32

Novel Bispecific Domain Antibody to LRP6 Inhibits Wnt and R-spondin Ligand-Induced Wnt Signaling and Tumor Growth

2016 · Heather Jackson, David Granger, et al. · Molecular Cancer Research · 28

Phase 1/2 Study of AUTO3 the First Bicistronic Chimeric Antigen Receptor (CAR) Targeting CD19 and CD22 Followed By an Anti-PD1 in Patients with Relapsed/Refractory (r/r) Diffuse Large B Cell Lymphoma (DLBCL): Results of Cohort 1 and 2 of the Alexander Study

2019 · Kirit M. Ardeshna, Maria A V Marzolini, et al. · Blood · 21

Study of AUTO3, the First Bicistronic Chimeric Antigen Receptor (CAR) Targeting CD19 and CD22, Followed By Anti-PD1 Consolidation in Patients with Relapsed/Refractory (r/r) Diffuse Large B Cell Lymphoma (DLBCL): Alexander Study

2018 · Kirit Ardeshna, Maria A V Marzolini, et al. · Blood · 11

Detection and quantification of integrated vector copy number by multiplex droplet digital PCR in dual-transduced CAR T cells

2023 · Wei Wang, Muhammad Al-Hajj, et al. · Molecular Therapy — Methods & Clinical Development · 9

890MO Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR.T cell, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL

2020 · E. Tholouli, W. Osborne, et al. · Annals of Oncology · 4

PDF

Abstract 2661: AUTO6NG overcomes immune suppressive mechanisms in the TME and demonstrate preclinical anti-tumor activity in GD2-expressing solid tumors

2020 · Margarida Neves, Lukas Stanczuk, et al. · Cancer Research · 1

Supplementary Figure 1 and Table 1 from Novel Bispecific Domain Antibody to LRP6 Inhibits Wnt and R-spondin Ligand-Induced Wnt Signaling and Tumor Growth

2023 · Heather Jackson, David Granger, et al.

Supplemental Figure Legend from Novel Bispecific Domain Antibody to LRP6 Inhibits Wnt and R-spondin Ligand-Induced Wnt Signaling and Tumor Growth

2023 · Heather Jackson, David Granger, et al.

Data from Novel Bispecific Domain Antibody to LRP6 Inhibits Wnt and R-spondin Ligand-Induced Wnt Signaling and Tumor Growth

2023 · Heather Jackson, David Granger, et al.

Works count: 29

Citation count: 14,520

H-index: 18

I10-index: 19